Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07243067 · ClinicalTrials.gov registry record
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
A clinical trial, sponsored by Mayo Clinic.
- Not yet
- Registry status
- 300
- Enrollment target
NCT07243067: Clinical Trial study, sponsored by Mayo Clinic.
NCT07243067 is a clinical trial that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07243067 has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- 300 participants
- Enrollment target
Study Summary
This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC). Aim 1 will use urine collected previously in biorepository. Aim 2 will prospectively collect blood specimens pre and post nephrectomy.
Primary Outcome
Differential protein expression analysis will be performed on stored urine samples from a biorepository to identify tdEV proteins in each renal cell carcinoma (RCC) subtype (clear-cell, papillary, and chromophobe) versus benign.
Interventions
- PROCEDURE Blood sample collection
- OTHER Proteomic profiling of urinary EVs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2027-04-30 |
What is known before NCT07243067 opens enrollment
NCT07243067 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Blood sample collection is the first listed.
NCT07243067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07243067 about?
NCT07243067 is a clinical study titled "Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer". This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC). Aim 1 will use urine collected previously in biorepository. Aim 2 will prospectively...
What is the current status of trial NCT07243067?
This trial is currently not yet recruiting. The enrollment target is 300 participants. The study started on 2026-07-15. Estimated completion is 2027-04-30.
What interventions are being tested in trial NCT07243067?
The interventions under investigation include: Blood sample collection (PROCEDURE), Proteomic profiling of urinary EVs (OTHER).
Who is sponsoring clinical trial NCT07243067?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI